Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of “Hold” from Analysts

Elanco Animal Health Incorporated (NYSE:ELAN) has earned a consensus recommendation of “Hold” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $17.14.

A number of research firms have issued reports on ELAN. Barclays upped their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 8th. Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 price target on shares of Elanco Animal Health in a research note on Thursday, September 19th. Finally, Morgan Stanley downgraded Elanco Animal Health from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $17.00 to $15.00 in a research report on Thursday, September 19th.

Institutional Investors Weigh In On Elanco Animal Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ELAN. Tidal Investments LLC boosted its stake in Elanco Animal Health by 25.5% during the 3rd quarter. Tidal Investments LLC now owns 84,578 shares of the company’s stock valued at $1,242,000 after acquiring an additional 17,206 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in Elanco Animal Health during the 3rd quarter worth $35,000. Geode Capital Management LLC boosted its holdings in shares of Elanco Animal Health by 0.8% during the third quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock valued at $115,623,000 after acquiring an additional 65,303 shares during the period. M&T Bank Corp boosted its stake in Elanco Animal Health by 5.9% during the 3rd quarter. M&T Bank Corp now owns 26,407 shares of the company’s stock valued at $388,000 after purchasing an additional 1,464 shares during the period. Finally, MML Investors Services LLC boosted its position in shares of Elanco Animal Health by 31.4% during the third quarter. MML Investors Services LLC now owns 15,454 shares of the company’s stock worth $227,000 after buying an additional 3,692 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 0.2 %

Shares of Elanco Animal Health stock opened at $13.39 on Thursday. The company has a 50-day moving average of $13.68 and a two-hundred day moving average of $14.72. The stock has a market cap of $6.62 billion, a PE ratio of 33.48, a price-to-earnings-growth ratio of 1.39 and a beta of 1.41. Elanco Animal Health has a 12-month low of $11.40 and a 12-month high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the previous year, the business posted $0.18 earnings per share. The firm’s quarterly revenue was down 3.6% compared to the same quarter last year. On average, research analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.